| Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.N Engl J Med | PMID 38819658无 PMCID | 2024-Jul-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.N Engl J Med | PMID 38959480无 PMCID | 2024-Jul-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.J Bone Joint Surg Am | PMID 38691582PMC11594069 | 2024-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension.Obstet Gynecol | PMID 38781591PMC11216857 | 2024-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.Obstet Gynecol | PMID 38949541PMC11219006 | 2024-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.Int J Radiat Oncol Biol Phys | PMID 37802226无 PMCID | 2024-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).Int J Radiat Oncol Biol Phys | PMID 38072326无 PMCID | 2024-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.Haematologica | PMID 38299578PMC11215383 | 2024-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.Cancer | PMID 38427287无 PMCID | 2024-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).J Rheumatol | PMID 38621793无 PMCID | 2024-Jul-01 | 0.95 | The study is not oncology-focused; it investigates rheumatoid arthritis. The primary efficacy outcomes are clinical response criteria (e.g., CDAI remission, DAS28-CRP <2.6, ACR20/50/70), which are not time-to-event endpoints like OS, PFS, DFS, EFS, RFS, or TTP, and there is no indication of Kaplan-Meier analysis or hazard ratios for such an endpoint. | 待处理 |
| RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.J Clin Oncol | PMID 38648575PMC11210946 | 2024-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).J Nucl Med | PMID 38664019PMC11218723 | 2024-Jul-01 | 0.95 | The study is an eligible human oncology randomized phase III trial with a primary time-to-event endpoint, but it evaluates a diagnostic imaging intervention (PSMA PET/CT) and lacks a drug-containing intervention, which is a required criterion. | 待处理 |
| A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.J Nucl Med | PMID 38844361无 PMCID | 2024-Jul-01 | 0.70 | The study meets criteria for oncology, human subjects, randomized design, Phase III status, and time-to-event endpoints. However, the primary intervention is a diagnostic imaging agent/procedure, not a drug-containing therapeutic intervention. Therefore, it is excluded. | 待处理 |
| Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.Int J Gynecol Cancer | PMID 38950925PMC11228198 | 2024-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.JAMA Netw Open | PMID 38980676PMC11234233 | 2024-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.JNCI Cancer Spectr | PMID 39067037PMC11316615 | 2024-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.J Geriatr Oncol | PMID 37211514无 PMCID | 2024-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.BJU Int | PMID 38009394无 PMCID | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of MC-003 solution for endoscopic mucosal or submucosal resection: a prospective, multicenter, randomized, triple-blinded, parallel-group, phase III study.Gastrointest Endosc | PMID 38184114无 PMCID | 2024-Jul | 0.95 | Study meets oncology, human, randomized, and phase III criteria with original results, but is excluded because the intervention is a non-drug procedural solution and the endpoints are not time-to-event efficacy outcomes. | 待处理 |
| Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.Ophthalmology | PMID 38253291无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).Eur Urol | PMID 38290964PMC12882065 | 2024-Jul | 0.85 | The record describes a Phase III randomized trial in human oncology with a primary time-to-event efficacy endpoint (biochemical recurrence-free survival). However, the intervention is a diagnostic imaging modality (PSMA-PET) and not a drug-containing regimen. Therefore, it does not meet the 'drug-containing intervention' criterion for inclusion. | 待处理 |
| Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).Am J Ophthalmol | PMID 38395329无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.J Allergy Clin Immunol | PMID 38431226无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.J Thorac Oncol | PMID 38460751无 PMCID | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.Mov Disord Clin Pract | PMID 38465885PMC11233834 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).Bone Marrow Transplant | PMID 38493275PMC11226393 | 2024-Jul | 0.95 | This record is for a non-randomized, observational study (ATOS) that compares its results to a previously reported Phase III randomized trial. It is not an original report of the randomized trial's results. | 待处理 |
| Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.Leuk Lymphoma | PMID 38501751无 PMCID | 2024-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.Clin Breast Cancer | PMID 38514306无 PMCID | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.Gynecol Oncol | PMID 38554625无 PMCID | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.J Am Acad Dermatol | PMID 38554938无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.J Allergy Clin Immunol Pract | PMID 38555079无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.Osteoporos Int | PMID 38573517PMC11211143 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.Eur Urol | PMID 38582713PMC11890201 | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes Metab | PMID 38602409无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.Esophagus | PMID 38607538PMC11199245 | 2024-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial.Ann Surg Oncol | PMID 38616209PMC11164758 | 2024-Jul | 0.45 | The metadata confirms an oncology, human, randomized, Phase III trial, but the reported outcome is postoperative morbidity, not a survival or time-to-event efficacy endpoint. Therefore, it is not eligible for the Kaplan-Meier digitization cohort. | 待处理 |
| Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.Diabetes Obes Metab | PMID 38618970无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).Radiother Oncol | PMID 38636708无 PMCID | 2024-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.Radiother Oncol | PMID 38636709无 PMCID | 2024-Jul | 0.90 | The study is a secondary biomarker analysis (correlating GARD with locoregional control) from a randomized Phase III trial. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, it does not present a primary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR from the original trial. The deterministic review correctly identified the lack of a time-to-event signal. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort. | 待处理 |
| D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.Contemp Clin Trials | PMID 38636725PMC7618164 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial.Lancet Respir Med | PMID 38643780无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Gastroenterol Hepatol | PMID 38670135无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials.Epilepsy Behav | PMID 38677101无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.Am J Clin Dermatol | PMID 38698175PMC11193693 | 2024-Jul | 0.95 | The study is a Phase III randomized trial of ruxolitinib cream for atopic dermatitis, which is a non-oncologic inflammatory skin condition. The efficacy endpoints are categorical or continuous measures (IGA-TS, EASI-75, NRS4) without a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). Therefore, it does not meet the oncology or time-to-event criteria for inclusion. | 待处理 |
| Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.Diabetes Obes Metab | PMID 38698650无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 38723644无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.Eur J Cancer | PMID 38749110无 PMCID | 2024-Jul | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).Eur J Drug Metab Pharmacokinet | PMID 38750386无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.Ann Oncol | PMID 38755096无 PMCID | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.HIV Med | PMID 38760011无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |